Group
HER(2) targeting TKI
Group Profile
| Therapeutic Class | Targeted Therapy |
| Drug Class | Tyrosine Kinase Inhibitors (TKIs) |
| Mechanism of Action | pan HER inhibitor |
| Drugs in group | Neratinib· Sevabertinib· Tucatinib· Zongertinib |
Study design
RT–Drug Timing Window
Study design
RT–Drug Timing Window
Radiobiological rationale for RT–drug interaction
Radiosensitizing in HER2-overexpressing tumors (↓HER2/AKT/ERK, delayed DSB repair, ↑apoptosis/senescence) without sensitizing HER2-negative cells (Amrell et al., Cancer Cell International, 2024; Yu et al., Oncotarget, 2016). Antigen/driver-restricted sensitization limits theoretical field side-effects, though the pan-HER class effect of diarrhea and mucocutaneous adverse events could overlap with RT-related GI/mucosal reactions.
The data above refer to patients treated with HER(2) targeting TKI as the sole drug class,
excluding any concurrent use of drugs from other groups.
Individual Drugs
Select a drug to view its individual evidence base (drug + SBRT, no other concurrent systemic drugs). Drugs without available data are shown greyed out.